Lupin launches generic Loteprednol Etabonate Ophthalmic Suspension in the US market, a bioequivalent to Lotemax, to treat eye ...

Lupin has launched a generic eye medication in the US, aimed at treating inflammation and pain. This new product is a generic ...

Loteprednol etabonate ophthalmic gel, 0.38%, is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery.

Lupin launches Loteprednol Etabonate Ophthalmic Suspension, 0.5%, a generic equivalent to Lotemax, for eye inflammation treatment.

Mumbai: Global pharma major Lupin Limited has launched Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United ...

Lupin announced that it has launched Loteprednol Etabonate Ophthalmic Suspension in the United States.

Lupin's share price rose today after the company announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the US market.

Loteprednol Etabonate Ophthalmic Gel is bioequivalent to Lotemax SM Ophthalmic Gel of Bausch & Lomb Inc and will be manufactured at Pithampur facility in India.

The stated product is a generic version of Lotemax SM ophthalmic gel, 0.38%. The was originally developed by Bausch & Lomb Inc. Lupin is the first-to-file exclusive for this product.

According to IQVIA MAT data for May 2025, Loteprednol Etabonate Ophthalmic Gel, 0.38% (Reference Listed Drug: Lotemax (R) SM) had estimated annual sales of $29 million in the U.S.

On Thursday, 2007 stocks advanced, 2040 declined and 152 remained unchanged on Bombay Stock Exchange with advance decline ...

Aldeyra Therapeutics (ALDX) stock in focus as the FDA accepts its resubmitted marketing application for lead drug reproxalap ...